Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + cadonilimab + standard chemotherapy for second-line advanced colorectal cancer
ChiCTR2400091176Phase 2Not yet recruiting
- Sponsor
- Xuancheng People's Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and cadonilimab in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by Xuancheng People's Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fruquintinibcadonilimab
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400091176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091176.